223 related articles for article (PubMed ID: 32533369)
1. Predicting reactivity to drug metabolism: beyond P450s-modelling FMOs and UGTs.
Öeren M; Walton PJ; Hunt PA; Ponting DJ; Segall MD
J Comput Aided Mol Des; 2021 Apr; 35(4):541-555. PubMed ID: 32533369
[TBL] [Abstract][Full Text] [Related]
2. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).
Knights KM; Rowland A; Miners JO
Br J Clin Pharmacol; 2013 Oct; 76(4):587-602. PubMed ID: 23362865
[TBL] [Abstract][Full Text] [Related]
3. Identification of enzymes responsible for the N-oxidation of darexaban glucuronide, the pharmacologically active metabolite of darexaban, and the glucuronidation of darexaban N-oxides in human liver microsomes.
Shiraga T; Yajima K; Teragaki T; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T
Biol Pharm Bull; 2012; 35(3):413-21. PubMed ID: 22382330
[TBL] [Abstract][Full Text] [Related]
4. Drug metabolism by flavin-containing monooxygenases of human and mouse.
Phillips IR; Shephard EA
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):167-181. PubMed ID: 27678284
[TBL] [Abstract][Full Text] [Related]
5. Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.
Xie G; Wong CC; Cheng KW; Huang L; Constantinides PP; Rigas B
Br J Pharmacol; 2012 Sep; 167(1):222-32. PubMed ID: 22489789
[TBL] [Abstract][Full Text] [Related]
6. [Drug glucuronidation and disposition in brain].
Zhang ZQ; Sheng L; Li Y
Yao Xue Xue Bao; 2016 Nov; 51(11):1674-80. PubMed ID: 29908109
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors.
den Braver-Sewradj SP; den Braver MW; Baze A; Decorde J; Fonsi M; Bachellier P; Vermeulen NPE; Commandeur JNM; Richert L; Vos JC
Eur J Pharm Sci; 2017 Nov; 109():96-110. PubMed ID: 28778465
[TBL] [Abstract][Full Text] [Related]
8. Modulation of UDP-glucuronosyltransferase activity by protein-protein association.
Ishii Y; Takeda S; Yamada H
Drug Metab Rev; 2010 Feb; 42(1):145-58. PubMed ID: 19817679
[TBL] [Abstract][Full Text] [Related]
9. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
[TBL] [Abstract][Full Text] [Related]
10. Nicotine-
Perez-Paramo YX; Chen G; Ashmore JH; Watson CJW; Nasrin S; Adams-Haduch J; Wang R; Gao YT; Koh WP; Yuan JM; Lazarus P
Cancer Epidemiol Biomarkers Prev; 2019 Feb; 28(2):311-320. PubMed ID: 30381441
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of dipropyl disulfide by rat liver phase I and phase II enzymes and by isolated perfused rat liver.
Teyssier C; Siess MH
Drug Metab Dispos; 2000 Jun; 28(6):648-54. PubMed ID: 10820136
[TBL] [Abstract][Full Text] [Related]
12. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.
Krueger SK; Williams DE
Pharmacol Ther; 2005 Jun; 106(3):357-87. PubMed ID: 15922018
[TBL] [Abstract][Full Text] [Related]
13. In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology.
Schulz-Utermoehl T; Spear M; Pollard CR; Pattison C; Rollison H; Sarda S; Ward M; Bushby N; Jordan A; Harrison M
Drug Metab Dispos; 2010 Oct; 38(10):1688-97. PubMed ID: 20634336
[TBL] [Abstract][Full Text] [Related]
14. Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex.
Ishii Y; Iwanaga M; Nishimura Y; Takeda S; Ikushiro S; Nagata K; Yamazoe Y; Mackenzie PI; Yamada H
Drug Metab Pharmacokinet; 2007 Oct; 22(5):367-76. PubMed ID: 17965520
[TBL] [Abstract][Full Text] [Related]
15. Metabolic interactions of rosmarinic acid with human cytochrome P450 monooxygenases and uridine diphosphate glucuronosyltransferases.
Kim SB; Kim KS; Kim DD; Yoon IS
Biomed Pharmacother; 2019 Feb; 110():111-117. PubMed ID: 30466000
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes.
Lapham K; Callegari E; Cianfrogna J; Lin J; Niosi M; Orozco CC; Sharma R; Goosen TC
Drug Metab Dispos; 2020 Dec; 48(12):1350-1363. PubMed ID: 33020067
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.
Williams JA; Hyland R; Jones BC; Smith DA; Hurst S; Goosen TC; Peterkin V; Koup JR; Ball SE
Drug Metab Dispos; 2004 Nov; 32(11):1201-8. PubMed ID: 15304429
[TBL] [Abstract][Full Text] [Related]
18. The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion.
Leoni C; Buratti FM; Testai E
Toxicol Appl Pharmacol; 2008 Dec; 233(2):343-52. PubMed ID: 18845175
[TBL] [Abstract][Full Text] [Related]
19. Some distinctions between flavin-containing and cytochrome P450 monooxygenases.
Cashman JR
Biochem Biophys Res Commun; 2005 Dec; 338(1):599-604. PubMed ID: 16112078
[TBL] [Abstract][Full Text] [Related]
20. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.
Cubitt HE; Houston JB; Galetin A
Pharm Res; 2009 May; 26(5):1073-83. PubMed ID: 19184618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
